Objectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant

Similar documents
Bridging the Gap: How to Transition from the NOACs to Warfarin

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

New Oral Anticoagulants. How safe are they outside the trials?

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Updates to the Alberta Human Services Drug Benefit Supplement

3/3/2015. Patrick Cobb, MD, FACP March 2015

Anticoagulants in Atrial Fibrillation

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

Cardiovascular Disease

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

National Guidance and New Protocols

Anticoagulation at the end of life. Rhona Maclean

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

East Kent Prescribing Group

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

FDA Approved Oral Anticoagulants

National Guidance and New Protocols

The Role of the Newer Anticoagulants

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Thrombosis and Hemostasis

Prior Authorization Guideline

Executive Summary. Motive for the request for advice

Traditional anticoagulants

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

How To Treat Aneuricaagulation

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

DVT/PE Management with Rivaroxaban (Xarelto)

New Oral Anticoagulant Drugs What monitoring if any is required?

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

The importance of adherence and persistence: The advantages of once-daily dosing

NWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

New Anticoagulants: What to Use What to Avoid

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

TSOAC Initiation Checklist

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

The Anticoagulated Patient A Hematologist s Perspective

STROKE PREVENTION IN ATRIAL FIBRILLATION

Cardiovascular Subcommittee of PTAC Meeting held 27 February (minutes for web publishing)

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

How To Manage An Anticoagulant

Introduction. Background to this event. Raising awareness 09/11/2015

Anticoagulant therapy

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Andrew Stoessel, PharmD PGY-1 Pharmacy Practice Resident Jackson Memorial Hospital

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Outpatient Anticoagulation Treatment Packet

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Warfarin. (Coumadin, Jantoven ) Taking your medication safely

Anticoagulation Essentials! Parenteral and Oral!

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation

News Release. Media Contacts: Kristina Chang Tel: (908) Mobile: (201)

Comparison between New Oral Anticoagulants and Warfarin

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

Clinical Assistant Professor University of Kansas School of Pharmacy. Objectives

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

How To Compare The New Oral Anticoagulants

CDEC FINAL RECOMMENDATION

Web appendix: Supplementary material. Appendix 1 (on-line): Medline search strategy

Title of Guideline. Thrombosis Pharmacist)

New Anticoagulants: When and Why Should I Use Them? Disclosures

Transcription:

Objectives Transitioning a Patient To & From a New Oral Anticoagulant How to switch from warfarin to rivaroxaban Discuss the Medicare donut hole How to switch from rivaroxaban to warfarin Home INR monitoring 2 Patient Background 67 year old white male with chronic atrial fibrillation Currently taking warfarin Significant difficulty making it into the office for INR checks & wanted an alternative Decided to switch patient to rivaroxaban from warfarin Rivaroxaban is only once a day dosing Requires no monitoring of INRs 3 4 1

Other Options Dabigatran- twice daily dosing Apixaban- had not yet hit market in 2013 (also twice a day dosing) Edoxaban- had also not yet hit the market How to Switch to Rivaroxaban? Stop warfarin and start rivaroxaban when INR less than 2 Manufacturer recommends stopping warfarin and starting rivaroxaban when INR less than 3 Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics, Inc. Updated periodically. Accessed April 6, 2015 5 Moll, S. Management of Rivaroxaban in Adults, UNC Health Care Guideline, May 2012Updated periodically. Accessed March 6, 2015 6 Starting Rivaroxaban Patient s last INRs over last 4 months 2.4, 3.1, 1.7, 3.1 Patient was started on rivaroxaban 20 mg PO daily No significant risk of bleeds in this patient felt safe with an INR under 3 Pt did very well on rivaroxaban Until 7 8 2

The Medicare Doughnut Hole The Serious Eats Doughnut Style Guide. (n.d.). Retrieved April 6, 2015, from http://sweets.seriouseats.com/2012/02/doughnut-style-guidedefinition--cake-yeast-old-fashioned-cruller.html 9 Doughnut Holes? The Medicare Coverage Gap, Explained. (2012, July 26). Retrieved April 6, 2015, from http://www.tricast.com/2012/07/doughnut-holes-the-medicare-coverage-gap-explained/ 10 Cost of Rivaroxaban With Medicare patient cost was around $40/month Out of pocket cost while in donut hole was around $300/month It was then decided to switch patient back from rivaroxaban to warfarin because of COST 11 12 3

Bridging to Warfarin Switching Back from Rivaroxaban to Warfarin Bridge between switching, due to reports of stroke from stopping rivaroxaban with no continuous anticoagulation The bridge could be done with rivaroxaban or with LMWH Hunter, M., Miller, S., Miller, A., & Reed, B. (2012, May 1). Retrieved March 6, 2015, from http://professionalsblog.clotconnect.org/wp-content/uploads/2012/05/unc- Xarelto-2012.pdf 14 Reason rivaroxaban was chosen Easy adherence for the patient Cheap cost for patient The reason for using LMWH is that rivaroxaban can increase INR independently for 48 hours after stopping Therefore the INR during the bridge therapy may not be accurate 15 Hunter, M., Miller, S., Miller, A., & Reed, B. (2012, May 1). Retrieved March 6, 2015, from http://professionalsblog.clotconnect.org/wp-content/uploads/2012/05/unc- Xarelto-2012.pdf 16 4

Switching Patient From Rivaroxaban to Warfarin Patient fairly stable on 5 mg of warfarin in the past There are no studies looking at converting rivaroxaban to warfarin specifically, but several sources for clinical recommendations Plan Overlap with rivaroxaban x 5 days or when INR is 2-3 Start on warfarin once patient has five tabs of rivaroxaban remaining Hunter, M., Miller, S., Miller, A., & Reed, B. (2012, May 1). Retrieved March 6, 2015, from http://professionalsblog.clotconnect.org/wp-content/uploads/2012/05/unc- Xarelto-2012.pdf 17 18 Note that rivaroxaban may increase INR. If kidney function poor (GFR<50), recommend shorter overlap Hunter, M., Miller, S., Miller, A., & Reed, B. (2012, May 1). Retrieved March 6, 2015, from http://professionalsblog.clotconnect.org/wp-content/uploads/2012/05/unc-xarelto- 2012.pdf 19 Bridging Rivaroxaban to Warfarin: Patient Results Day INR Rivaroxaban Warfarin 1 2.8 Cont rivaroxaban 20mg Start 5mg warfarin 3 1.3 Cont rivaroxaban 5 7.8 Stop rivaroxaban 7.5mg warfarin for 1day, then Cont warfarin 5mg Hold warfarin for 2 days and restart 7 1.8 Cont 5mg warfarin 11 2.4 Cont 5mg warfarin, cont rechecks weekly until normalized. 20 5

Home Monitoring Patient is now checking INR at home For services furnished on or after March 19, 2008, Medicare will cover for the use of home PT/INR monitoring for chronic, oral anticoagulation management for patients with Approved Indications for Home Monitoring Mechanical Heart Valve (MHV) Atrial Fibrillation Venous Thromboembolism, Deep Vein Thrombosis (DVT), or Pulmonary Embolism (PE) Hypercoagulable state (n.d.). Retrieved March 1, 2015, from http://www.cms.gov/medicare-coveragedatabase/details/ncd-details.aspx?ncdid=269&ver=2 21 (n.d.). Retrieved March 1, 2015, from http://www.cms.gov/medicarecoverage-database/details/ncd-details.aspx?ncdid=269&ver=2 22 Home Monitoring Anticoagulated for at least 3 months Face-to-face educational program (Company did training for me) The patient continues to correctly use the device No more than once a week testing (n.d.). Retrieved March 1, 2015, from http://www.cms.gov/medicare-coveragedatabase/details/ncd-details.aspx?ncdid=269&ver=2 23 Alere INRatio 2 PT/INR Monitoring Systems. (n.d.). Retrieved March 1, 2015, from http://www.alere.com/us/en/product-details/inratio-pt-inr-monitoring-systems.html 24 6

Alere INRatio 2 PT/INR Monitoring Systems. (n.d.). Retrieved March 1, 2015, from http://www.alere.com/us/en/product-details/inratio-pt-inrmonitoring-systems.html 25 7